Novartis to buy Seattle-based Chinook for up to $3.5bn
Novartis has agreed to acquire Seattle-based biotech firm Chinook Therapeutics for up to $3.5 billion to boost its late-stage drug development line-up with a new treatment for a rare severe kidney disease.
Business
• 12 Jun 23
